<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE OF REVIEW: Prevention of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) therapies in patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> will be reviewed </plain></SENT>
<SENT sid="1" pm="."><plain>RECENT FINDINGS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> utilization in patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> has resulted in significantly improved long-term survival </plain></SENT>
<SENT sid="2" pm="."><plain>However, there is growing evidence that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks are associated with increased morbidity and mortality </plain></SENT>
<SENT sid="3" pm="."><plain>As a result, there is increasing emphasis on the treatment strategies to avoid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies </plain></SENT>
<SENT sid="4" pm="."><plain>Optimal <z:hpo ids='HP_0001635'>heart failure</z:hpo> management with medical as well as cardiac resynchronization therapy when indicated is an essential part of treatment; however, adjunctive measures may be necessary to suppress <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, prevent unnecessary shocks, and improve quality of life </plain></SENT>
<SENT sid="5" pm="."><plain>SUMMARY: Device programming can help avoid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies by delaying time to detection, increasing detection rate cutoffs, and discriminating between supraventricular and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Still, as patients live longer with advanced stages of <z:hpo ids='HP_0001635'>heart failure</z:hpo>, there will be a need to suppress sustained <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> that would otherwise require <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Antiarrhythmic drugs offer a noninvasive option to help suppress <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>With more experience and better catheter mapping and ablation techniques, there is a movement toward an early invasive strategy for <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> management in patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
</text></document>